M. Keskinkılıç Et Al. , "The Increased Creatinine Level Secondary to Use of CDK 4/6 Inhibitor and Endocrine Therapy: Real Life Data," Breastanbul , İstanbul, Turkey, pp.55, 2022
Keskinkılıç, M. Et Al. 2022. The Increased Creatinine Level Secondary to Use of CDK 4/6 Inhibitor and Endocrine Therapy: Real Life Data. Breastanbul , (İstanbul, Turkey), 55.
Keskinkılıç, M., Semiz, H. S., Yavuzşen, T., & Karaoğlu, A., (2022). The Increased Creatinine Level Secondary to Use of CDK 4/6 Inhibitor and Endocrine Therapy: Real Life Data . Breastanbul (pp.55). İstanbul, Turkey
Keskinkılıç, MERVE Et Al. "The Increased Creatinine Level Secondary to Use of CDK 4/6 Inhibitor and Endocrine Therapy: Real Life Data," Breastanbul, İstanbul, Turkey, 2022
Keskinkılıç, MERVE Et Al. "The Increased Creatinine Level Secondary to Use of CDK 4/6 Inhibitor and Endocrine Therapy: Real Life Data." Breastanbul , İstanbul, Turkey, pp.55, 2022
Keskinkılıç, M. Et Al. (2022) . "The Increased Creatinine Level Secondary to Use of CDK 4/6 Inhibitor and Endocrine Therapy: Real Life Data." Breastanbul , İstanbul, Turkey, p.55.
@conferencepaper{conferencepaper, author={MERVE KESKİNKILIÇ Et Al. }, title={The Increased Creatinine Level Secondary to Use of CDK 4/6 Inhibitor and Endocrine Therapy: Real Life Data}, congress name={Breastanbul}, city={İstanbul}, country={Turkey}, year={2022}, pages={55} }